Bristol-Myers Squibb Company (BMY)
Return on total capital
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 9,591,000 | 9,751,000 | 9,846,000 | 9,972,000 | 8,927,000 | 8,958,000 | 8,931,000 | 8,545,000 | 9,412,000 | -2,865,000 | -2,747,000 | -2,645,000 | -5,471,000 | 4,779,000 | 3,727,000 | 3,640,000 | 5,610,000 | 7,011,000 | 7,666,000 | 6,327,000 |
| Long-term debt | US$ in thousands | 36,653,000 | 32,137,000 | 34,656,000 | 35,078,000 | 35,056,000 | 36,966,000 | 37,107,000 | 37,450,000 | 39,605,000 | 39,677,000 | 42,503,000 | 44,505,000 | 48,336,000 | 41,364,000 | 41,853,000 | 42,844,000 | 43,387,000 | 24,390,000 | 24,433,000 | 5,635,000 |
| Total stockholders’ equity | US$ in thousands | 29,430,000 | 28,998,000 | 31,973,000 | 31,824,000 | 31,061,000 | 32,671,000 | 32,600,000 | 31,580,000 | 35,946,000 | 37,213,000 | 36,808,000 | 37,605,000 | 37,822,000 | 50,158,000 | 49,094,000 | 49,911,000 | 51,598,000 | 17,648,000 | 16,049,000 | 15,218,000 |
| Return on total capital | 14.51% | 15.95% | 14.78% | 14.91% | 13.50% | 12.86% | 12.81% | 12.38% | 12.46% | -3.73% | -3.46% | -3.22% | -6.35% | 5.22% | 4.10% | 3.92% | 5.91% | 16.68% | 18.94% | 30.34% |
December 31, 2023 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $9,591,000K ÷ ($36,653,000K + $29,430,000K)
= 14.51%
Bristol-Myers Squibb Co.'s return on total capital has been relatively stable over the past eight quarters, ranging from a low of 9.11% in Q1 2022 to a high of 13.43% in Q1 2023. The company's return on total capital peaked in Q1 2023 at 13.43%, indicating that for every dollar of total capital employed, Bristol-Myers Squibb generated a return of 13.43 cents. This suggests efficient utilization of the company's total capital to generate profits during that period. Overall, the trend in return on total capital shows consistent performance in generating returns for the company's capital providers over the analyzed period.
Peer comparison
Dec 31, 2023